An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.
Condition or disease
Cytomegalovirus RetinitisHIV Infections
Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
13 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Stable CMV retinitis.
Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days.
No permanent central IV catheter at present.
Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis.
Consent of guardian if less than legal age of consent.
Patients with the following symptoms or conditions are excluded:
Require continuation of concomitant medications precluded by this protocol.
Intravitreal anti-CMV treatment.
Any other concomitant medications precluded by the protocol.
Patients with the following prior condition are excluded:
History of hypersensitivity to acyclovir or ganciclovir.